A successful start into the new year: New Growth Funding for MedTech Company Mecuris GmbH

German med-tech company Mecuris GmbH has successfully concluded a new funding round amounting to 3.6 million euros. In addition to the seed investors Bayern Kapital and High-Tech Gründerfonds (HTGF), the international investment company Mulcan, life science venture capital investor Vesalius Biocapital, and Sana Kliniken AG, one of the top five hospital chains in Germany, are once again also on board.

Clear yes from the O&P industry to digitalization
The Munich-based start-up has set out to revolutionize the O&P industry through its innovative Mecuris Solution Platform. This online platform represents a digital workshop, in which patient-specific prostheses and orthoses can be quickly and easily tailored and realised using 3D printing. The digital process chain behind it enables CPOs and users to co-create an aid optimized in terms of color, form and function.
The primary goal at Mecuris was initially to familiarize orthopaedic professionals with the online platform to digitize traditional crafts – where sensibly possible and time-saving. Last year, the company came much closer to this goal:

“The development of Mecuris into a provider of digital algorithms is now clearly accepted by partners in orthopedic patient care as a step into the future. In order to consistently continue along this path and in view of the milestones achieved in 2019, all investors in the Serie-A round have decided, as planned, to continue to provide the company with the necessary resources,” says industry expert Johannes Schneider-Littfeld, who took over the chairmanship of the Mecuris Advisory Board in mid-2019.

In 2020, the orthotics sector will also become digital.
Mecuris will use the funds both to increase market penetration of the European market and to expand its platform in the field of orthotics, which is planned for the end of March. From then on, the Digital Prosthetic Workshop for the creation of individual prostheses will be supplemented by the Digital Orthotic Workshop. This will provide CPOs with a simple, intuitive and, above all, time-saving way of creating orthoses completely or using partial steps in a web-based workflow.

About Mecuris
Mecuris teams up with certified prosthetists and orthotists (CPOs) to move orthopedic care into the digital age. Bringing together 3D technologies into one intuitive Mecuris Solution Platform, the company found a way to simplify the CPOs work and transform the way to design and use orthopedic devices. Mecuris enriches wearers’ lives by enabling medical professionals to design their product ideas on our intuitive digital platform – without any CAD design knowledge. This means patients can quickly regain their mobility, show their individuality and become active again faster. Thanks to full CE-mark and ISO certification, Mecuris’ products meet the highest safety standards and are reimbursed by all health insurance funds in Germany.

Mecuris – You. Create.

Contact
Mecuris
Eva Stahl
Head of Marketing
pr@mecuris.com
T.: +49 89 20 00 57-340
www.mecuris.com

Contact
Fortis PR
Gloria Huppert / Ramona Daub
mecuris@fortispr.de
T.: +49 89 452 278 – 18/- 15

About Bayern Kapital
Bayern Kapital GmbH, based in Landshut, was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank . As the venture capital organization of the State of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria. Presently Bayern Kapital manages twelve investment funds with a total volume of around €385m. So far, it has invested almost €308m in 272 innovative companies in the fields of technology in various sectors including life science, software and IT, medical technology, materials and new materials, nanotechnology and environmental technology. In this way, more than 5000 long-term jobs in sustainable companies have been created in Bavaria.
www.bayernkapital.de/financing-innovation/

About MII Mulcan International Investments GmbH
MULCAN is an international investment company focusing on growth investment opportunities in the manufacturing, industrial and service sectors across Europe (with specific emphasis on Eastern Europe), the Middle East and in other developing countries.
www.mulcan.de

About Vesalius Biocapital Partners S.à r.L,
Vesalius Biocapital (Vesalius), the specialist life sciences venture capital investor, has supported companies active in human health through venture capital funds since 2007. Since inception, Vesalius has raised over €260 million in three funds and contributed to the development of over 30 companies. The investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs, with a strong focus on an exit within five years.
www.vesaliusbiocapital.com

About Sana Kliniken AG
Sana Kliniken AG is an important provider of integrated healthcare services. It operates more than 50 hospitals and treats more than 2.2 million patients per year with 34,000 employees. In addition to its core business, Sana owns and operates other specialised facilities such as rehabilitation clinics, nursing homes and medical care centres. The Sana Digital division was founded in 2016 with the aim of promoting the process of digital transformation within the Sana Group.
www.sana.de

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 560 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences. To date, external investors have injected over EUR 2 billion into the HTGF portfolio via more than 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.

Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Contact
High-Tech Gründerfonds
Dr. Frank Hensel
Schlegelstraße 2
53113 Bonn
T.: +49 228 823 00 – 142
f.hensel@htgf.de
www.htgf.de